MedTrace Logo

Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy

NCT01571518 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2012-04-05

No results posted yet for this study

Summary

After resection of lymph node positive breast cancer, the injection duration and timing of Granulocyte-colony stimulating factor (G-CSF) could affect the neutropenia with TAC (Taxotere, Adriamycin, cyclophosphamide) chemotherapy.

Conditions

Interventions

DRUG

late leukostim

injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy

DRUG

early leukostim

injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy

Sponsors & Collaborators

  • Dong-A Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Hyuk moon Kim

    lead OTHER

Principal Investigators

  • Chul Wan Lim, MD,PhD · Soonchunhyang U Puchun Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • South Korea

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01571518 on ClinicalTrials.gov